Description
Indication & Scope
RuiTanNing® Fosrolapitant and Palonosetron Hydrochloride for Injection serves as a prevention of acute and delayed nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC)in adult patients.
- Mechanism: Combined dual anti-emetic mechanism. Palonosetron is a 5-HT3 receptor antagonist that blocks acute chemotherapy-induced vomiting; Fosrolapitant is a long-acting NK1 receptor antagonist that inhibits delayed nausea and vomiting by blocking substance P signaling.
- Drug class: Fixed-combination injectable anti-emetic prescription medicine, 5-HT3 + NK1 receptor antagonist compound.
- Clinical use: One-time pre-chemotherapy injection to control both acute and delayed chemotherapy-induced nausea and vomiting for high-emetic risk chemotherapy regimens.
| Generic Name | Fosrolapitant and Palonosetron Hydrochloride for Injection |
| Brand Name | RuiTanNing |
| Ingredient | Fosrolapitant and Palonosetron Hydrochloride |
| Dosage Form | Injection |
| Package | Vorospiracetam 218mg + Palonosetron Hydrochloride 0.25mg*1 vial/box |
| Conditions Treated | Acute and delayed nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC) in adults |
| Taboos | Severe hypersensitivity to palonosetron, fosrolapitant or injection excipients; patients with congenital long QT syndrome |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store sealed at 20°C–25°C, protected from light |
| Manufacturer | ShengDi Pharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250027 |
| Approval Date | May 27, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Single fixed dual-drug intravenous bolus injection administered 30 minutes before chemotherapy initiation.
Time: Complete injection within 30 minutes prior to chemotherapy infusion on treatment days.
Instructions for use: Administer via intravenous bolus; no dose splitting required; one single injection covers full chemotherapy cycle anti-emetic demand.
Interaction: Fosrolapitant inhibits CYP3A4, elevates systemic exposure of CYP3A4 substrate drugs, dose monitoring is required for co-administration.
Side effects: Mild headache, constipation, fatigue, transient QT interval prolongation (rare).
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the clinical purpose of Fosrolapitant and Palonosetron Hydrochloride for Injection?
It prevents both acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy.
What two antiemetic mechanisms does Fosrolapitant and Palonosetron Hydrochloride for Injection combine?
It combines 5-HT3 receptor inhibition for acute vomiting and NK1 receptor inhibition for delayed vomiting.
Which patients cannot use Fosrolapitant and Palonosetron Hydrochloride for Injection?
Patients with congenital long QT syndrome and severe drug hypersensitivity are contraindicated.
What drug interaction should be noticed when using Fosrolapitant and Palonosetron Hydrochloride for Injection?
Fosrolapitant inhibits CYP3A4 and may increase the blood concentration of other CYP3A4 substrate drugs.
RuiTanNing® | Fosrolapitant and Palonosetron Hydrochloride for Injection | HEC | DengYueRX
INN: Fosrolapitant and Palonosetron Hydrochloride for Injection
Indications: Prevention of acute and delayed nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC)
Dosage Form: Injection
Strength: Vorospiracetam 218mg + Palonosetron Hydrochloride 0.25mg/vial
